title: Asymptomatic pancreatic cystic neoplasm: a cost-effectiveness analysis of different strategies of management.
abstract: BACKGROUND
  Optimal management of asymptomatic pancreatic cystic neoplasm is not known.
  
  
  OBJECTIVE
  In a decision analysis, the cost-effectiveness of different strategies for managing solitary, asymptomatic pancreatic cystic neoplasm were compared.
  
  
  METHODS
  Three strategies were examined in a Markov model with a third-party-payer perspective. In strategy I, the natural history of the lesion was followed without any specific intervention. In strategy II, an aggressive surgical approach was considered in that all patients were considered for resection. In strategy III, an initial EUS-guided FNA with cyst fluid analysis was performed for risk stratification, and patients with mucinous cysts were considered for resection. Transitional probabilities, discounted cost, and utility values to estimate quality-adjusted life years were obtained from published information. An operability risk score based on patient age, comorbidity, and size and location of the cyst was developed to estimate the probability of surgical resection.
  
  
  RESULTS
  In the baseline analysis, strategy III yielded the highest quality-adjusted life years with an acceptable incremental cost-effectiveness ratio. In a Monte Carlo analysis, the relative risk of patients developing unresectable pancreatic cancer was decreased in strategy III compared to the other strategies. Although threshold analyses identified few important parameters influencing the conclusion of the analysis, operability risk score was the critical determinant of the optimal management strategy.
  
  
  CONCLUSIONS
  Indirect costs were not considered in this analysis.
  
  
  CONCLUSIONS
  For asymptomatic patients with incidental solitary pancreatic cystic neoplasm, a blanket policy of surgical resection for all patients cannot be justified. A strategy based on risk stratification of malignant potential by EUS-guided FNA and cyst fluid analysis is the most cost-effective strategy.
authors: Division of Gastroenterology, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA. Das.ananya@mayo.edu
authors: Ananya
authors: A
authors: Das
authors: Saowanee
authors: S
authors: Ngamruengphong
authors: Shweta
authors: S
authors: Nagendra
authors: Amitabh
authors: A
authors: Chak
mesh_terms: D044963:Biopsy, Fine-Needle; D003362:Cost-Benefit Analysis; D003661:Decision Support Techniques; D006801:Humans; D008390:Markov Chains; D018803:Models, Economic; D009010:Monte Carlo Method; D010179:Pancreas / Q000473:pathology*; D010190:Pancreatic Neoplasms / Q000191:economics* / Q000473:pathology / Q000628:therapy*; D019057:Quality-Adjusted Life Years